Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Targeted Oncology
Published in: Targeted Oncology 4/2016

01-08-2016 | Therapy in Practice

Severe Hyponatremia and Immune Nephritis Following an Initial Infusion of Nivolumab

Authors: Jeremy W. Vandiver, Zachary Singer, Cara Harshberger

Published in: Targeted Oncology | Issue 4/2016

Login to get access

Abstract

Anti-programmed cell death-1 (PD-1) antibodies pembrolizumab and nivolumab are becoming increasingly important in the treatment of melanoma and non-small cell lung cancer. These agents are known to induce many immune-related adverse events, but rapid-onset nephritis and immune-related hyponatremia have not been described to date. We describe the case of an adult patient who developed severe hyponatremia and rapid-onset nephritis following the first infusion of nivolumab for metastatic melanoma.
https://static-content.springer.com/image/art%3A10.1007%2Fs11523-016-0426-9/MediaObjects/11523_2016_426_Figa_HTML.gif
Literature
1.
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.CrossRefPubMedPubMedCentral
2.
Robert C, Long GV, Brady B, Dutriaux C, Maio M, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30.CrossRefPubMed
3.
Postow MA, Chesney J, Pavlick AC, Robert C, Grossman K, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–17.CrossRefPubMed
4.
Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375–84.CrossRefPubMed
5.
Opdivo [package insert]. Princeton, NJ: Bristol-Meyers Squibb; 2016.
6.
7.
8.
Barbee MS, Ogunniyi A, Horvat TZ, Dang T. Current status and future directions of the immune checkpoint inhibitors ipilmumab, pembrolizumab, and nivolumab in oncology. Ann Pharmacother. 2015;49(8):907–37.CrossRefPubMed
9.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.CrossRefPubMed
Metadata
Title
Severe Hyponatremia and Immune Nephritis Following an Initial Infusion of Nivolumab
Authors
Jeremy W. Vandiver
Zachary Singer
Cara Harshberger
Publication date
01-08-2016
Publisher
Springer International Publishing
Published in
Targeted Oncology / Issue 4/2016
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-016-0426-9

Other articles of this Issue 4/2016

Targeted Oncology 4/2016 Go to the issue

Review Article

Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC)

Original Research Article

Preclinical Study of a Combination of Erlotinib and Bevacizumab in Early Stages of Unselected Non-Small Cell Lung Cancer Patient-Derived Xenografts

Therapy in Practice

Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report

Review Article

Ramucirumab Clinical Development: an Emerging Role in Gastrointestinal Tumors

Short Communication

Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy

Original Research Article

Novel TNF-related Apoptotic-inducing Ligand-based Immunotoxin for Therapeutic Targeting of CD25 Positive Leukemia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits